Suggestions
Kevin Krause
Vice President - Clinical Sciences & Development Operations at AN2 Therapeutics, Inc.
Professional Background
Kevin Krause is a highly regarded biotechnology executive with over 22 years of extensive experience in Research and Development (R&D), Clinical Development, Product Launch, Commercial Strategy, and Business Development, focusing on Infectious Diseases and Respiratory Medicine. Throughout his prolific career, Kevin has demonstrated an exceptional ability to translate competitive intelligence into effective regulatory and commercial strategies. His expertise lies in synthesizing quantitative market research, scientific reviews, and competitive risk assessments to provide concise presentations to Executive and C-level management highlighting potential in-licensing, acquisition targets, and portfolio divestitures.
Kevin is known for his impressive functional leadership experience within global, cross-disciplinary teams that span all phases of R&D—from early discovery through Phase 3 and product launch—across multiple prominent brands. He has played pivotal roles in the development and commercialization of therapies such as Vibativ™ (telavancin), Teflaro™ (ceftaroline fosamil), Colobreathe™ (inhaled colistimethate sodium), AVYCAZ (ceftazidime-avibactam), Zemdri™ (plazomicin), and Quinsair™ (inhaled levofloxacin). His ability to collaborate effectively with diverse teams—including R&D, Commercial, Business Development, Medical Affairs, and upper management—ensures that strategic project and therapeutic area decisions are well-informed and timely.
Alongside his professional achievements, Kevin possesses extensive department leadership and management experience. He has oversaw personnel and budget decisions for a Clinical Development team of over 30 members, illustrating his capability to lead teams through complex scientific challenges and drive organizational success. Kevin’s authority in the field is further reflected in his prolific contributions to scientific literature and conferences, having authored 50 peer-reviewed research articles and 100+ poster abstracts and presentations for international conferences and significant Regulatory Agency workshops (FDA and EMA). Notably, he is also the lead inventor of one patent, showcasing his innovative approach to biotechnology.
Education and Achievements
Kevin Krause's educational foundation is rooted in a Bachelor of Science degree in Cell and Molecular Biology, complemented by a Minor in Chemistry, acquired from San Francisco State University. He furthered his academic credentials with an MBA in Finance and Corporate Strategy from the prestigious University of California, Berkeley's Walter A. Haas School of Business. This combination of scientific acumen and business strategy equips Kevin with a unique perspective that is vital in today’s rapidly evolving biopharmaceutical industry.
His academic journey began at Junipero Serra High School, where he laid the groundwork for his passion for science and inquiry. The blend of rigorous academic training and burgeoning practical experience has positioned Kevin as a thought leader in biotechnology strategy and clinical development.
In his current role as Vice President of Clinical Sciences & Development Operations at AN2 Therapeutics, Inc., Kevin continues to influence the future of biopharmaceutical innovation. Previously, he served as an Advisor at BioAmp Diagnostics, Inc., where he shared his expertise in developing strategies for infectious disease diagnostics.
Achievements
Kevin Krause's career is marked by numerous noteworthy achievements. His contributions to the field of biotechnology are evidenced by his extensive authorial work, which includes 50 peer-reviewed research articles and significant presentations at international conferences, reflecting his commitment to advancing knowledge in infectious diseases and respiratory medicine. Kevin’s regular interactions with cross-functional teams and board members exemplify his ability to communicate complex scientific concepts to stakeholders at all levels.
Moreover, Kevin's strategic insight into clinical development has led to successful product launches and the establishment of effective commercial strategies that resonate within the industry. His management experience overseeing a Clinical Development team demonstrates his capability in leading diverse individuals towards common goals, managing resources, and delivering high-quality scientific outcomes—a skill set that is invaluable in the biotech arena.
In addition to his leadership in clinical development and strategic commercial planning, Kevin’s role as the lead inventor on a patent underscores his contribution to innovative thinking in biotechnology, allowing for the translation of scientific research into applicable solutions that benefit patients and healthcare providers alike.
Through his extensive experience and notable achievements, Kevin Krause has solidified his position as a leader in the biotechnology sector. His strategic foresight, combined with an undivided commitment to scientific excellence, positions him not only as an asset to AN2 Therapeutics but as a prominent figure in the ongoing fight against infectious diseases and the development of respiratory therapies.
In summary, Kevin Krause's impressive career trajectory, bolstered by a robust educational background, extensive expertise, and significant contributions to biotechnology, renders him a reputable executive whose work continues to enhance public health standards globally.
